Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
Filing exhibits
VTGN similar filings
- 20 Mar 18 VistaGen Therapeutics Receives a Notice of Allowance for Another Key
- 8 Mar 18 VistaGen Therapeutics Receives Notice of Allowance for a Key U.S. Patent Covering Treatment of Depression with AV-101
- 13 Feb 18 VistaGen Therapeutics Reports Third Quarter Fiscal 2018 Financial Results
- 30 Jan 18 VistaGen Therapeutics Issues Letter to Stockholders as Company Prepares to Initiate AV-101 Phase 2 Study for Major Depressive Disorder
- 8 Jan 18 VistaGen Therapeutics Receives FDA Fast Track Designation for AV-101 for the Treatment of Major Depressive Disorder
- 13 Dec 17 VistaGen Announces Closing of $15,000,000 Underwritten Offering of Common Stock and Warrants to Purchase Common Stock
- 8 Dec 17 VistaGen Therapeutics Expands Stem Cell Patent Portfolio with New U.S. Patent
Filing view
External links
